St. Charles Health System

stcharleshealthcare.org

St. Charles Health System, Inc., headquartered in Bend, Ore., owns and operates St. Charles Bend, Madras, Redmond and Prineville. It also owns family care clinics in Bend, Prineville, Redmond and Sisters. St. Charles is a private, not-for-profit Oregon corporation and is the largest employer in Central Oregon with more than 3,800 caregivers. In addition, there are more than 350 active medical staff members and nearly 200 visiting medical staff members who partner with the health system to provide a wide range of care and service to our communities.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

INDUSTRIAL IMPACT

SARTORIUS STEDIM BIOTECH COMPLETES ACQUISITION OF NOVASEP'S CHROMATOGRAPHY DIVISION

Sartorius Stedim Biotech S.A. | February 08, 2022

news image

Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced today that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 e...

Read More

MEDTECH

GINKGO BIOWORKS ANNOUNCES STRATEGIC PURCHASE OF EPIDEMIOLOGICAL DATA INFRASTRUCTURE ASSETS

Ginkgo Bioworks | August 20, 2022

news image

Ginkgo Bioworks the leading horizontal platform for cell programming, announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation. Under the terms of the deal, Ginkgo will assume ownership of proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts. Ginkgo also expects to integrate several ongoing epidemio...

Read More

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More

MEDTECH

HALO LABS LAUNCHES THE AURA GT™ FOR GENE THERAPY PRODUCT QUALITY

Halo Labs | October 05, 2021

news image

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, Aura GT. Aura GT is part of the next generation in Halo Labs' popular family of instruments. Using Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM), Aura GT can distinguish aggregated capsids from contaminants, carrier proteins, and other particles that might adversely harm patients. Unique to Aura GT is...

Read More
news image

INDUSTRIAL IMPACT

SARTORIUS STEDIM BIOTECH COMPLETES ACQUISITION OF NOVASEP'S CHROMATOGRAPHY DIVISION

Sartorius Stedim Biotech S.A. | February 08, 2022

Sartorius Stedim Biotech, a leading partner of the biopharma industry, announced today that it closed the acquisition of the Novasep chromatography division as of February 7, 2022, following approval by the U.S. Federal Trade Commission. The transaction had already been agreed upon at the beginning of 2021. The business acquired generated sales of around 40 million euros in 2020 at a double-digit profit margin; final figures for 2021 are not yet available. The majority of the approximately 100 e...

Read More
news image

MEDTECH

GINKGO BIOWORKS ANNOUNCES STRATEGIC PURCHASE OF EPIDEMIOLOGICAL DATA INFRASTRUCTURE ASSETS

Ginkgo Bioworks | August 20, 2022

Ginkgo Bioworks the leading horizontal platform for cell programming, announced the purchase of certain epidemiological data infrastructure assets from Baktus, Inc., a Delaware-based public benefit corporation. Under the terms of the deal, Ginkgo will assume ownership of proprietary datasets, modeling and analytic tools, and a software platform with the capabilities to track, model, and forecast epidemics and associated risks and impacts. Ginkgo also expects to integrate several ongoing epidemio...

Read More
news image

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More
news image

MEDTECH

HALO LABS LAUNCHES THE AURA GT™ FOR GENE THERAPY PRODUCT QUALITY

Halo Labs | October 05, 2021

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest product, Aura GT. Aura GT is part of the next generation in Halo Labs' popular family of instruments. Using Backgrounded Membrane Imaging (BMI) and Fluorescence Membrane Microscopy (FMM), Aura GT can distinguish aggregated capsids from contaminants, carrier proteins, and other particles that might adversely harm patients. Unique to Aura GT is...

Read More